Fenfluramine Gets Priority Review for Lennox-Gastaut Syndrome

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for fenfluramine, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

An amphetamine derivative, fenfluramine was initially developed as an appetite suppressant and is believed to work through serotonergic mechanisms. The sNDA submission is supported by data from a global randomized, placebo-controlled phase 3 trial (ClinicalTrials.gov Identifier: NCT03355209) that compared the efficacy and safety of fenfluramine with placebo in 263 patients aged 2 to 35 years with LGS. 

Findings showed that treatment with fenfluramine 0.7mg/kg/day met the primary endpoint demonstrating superior reductions in the frequency of drop seizures compared with placebo (P =.0012). A statistically significant improvement in the proportion of patients with a clinically meaningful reduction (50% or greater) in drop seizure frequency (secondary efficacy endpoint) was also observed with fenfluramine. 

The sNDA also includes long-term safety and efficacy data from ongoing open-label extension trials. The safety profile of fenfluramine was found to be consistent with that observed in previous studies for Dravet syndrome.


Continue Reading

A Prescription Drug User Fee Act (PDUFA) target date of March 25, 2022 has been set for the application.

Fenfluramine, a schedule IV controlled substance, is currently marketed under the brand name Fintepla® and is approved for the treatment of seizures associated with Dravet syndrome. The product is available as a cherry-flavored oral solution containing 2.2mg/mL of fenfluramine. 

References

  1. Zogenix announces US FDA acceptance for Priority Review of supplemental New Drug Application for Fintepla® (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). News release. Zogenix, Inc. Accessed December 1, 2021. https://www.globenewswire.com/news-release/2021/12/01/2344064/0/en/Zogenix-Announces-U-S-FDA-Acceptance-for-Priority-Review-of-Supplemental-New-Drug-Application-for-FINTEPLA-Fenfluramine-for-the-Treatment-of-Seizures-Associated-with-Lennox-Gastaut.html. 
  2. Zogenix submits supplemental New Drug Application for Fintepla® (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome. News release. Zogenix, Inc. September 28, 2021. Accessed December 1, 2021. https://zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-submits-supplemental-new-drug-application-finteplar.

Source Link


DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

DrAbout.Net

The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button